[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 25, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 65, "title": "Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 570990, "exercisedValue": 0, "unexercisedValue": 11528577}, {"maxAge": 1, "name": "Mr. Matthew  Pulisic", "age": 40, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 67, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 55, "title": "General Counsel & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 53, "title": "Senior Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 79, "title": "Chief Medical Officer", "yearBorn": 1945, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 67, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.46, "open": 5.4, "dayLow": 5.2608, "dayHigh": 5.76, "regularMarketPreviousClose": 5.46, "regularMarketOpen": 5.4, "regularMarketDayLow": 5.2608, "regularMarketDayHigh": 5.76, "beta": -1.51, "forwardPE": -4.5126886, "volume": 261411, "regularMarketVolume": 261411, "averageVolume": 216318, "averageVolume10days": 324700, "averageDailyVolume10Day": 324700, "bid": 4.04, "ask": 6.79, "bidSize": 200, "askSize": 200, "marketCap": 184434000, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 8.668, "priceToSalesTrailing12Months": 23054.25, "fiftyDayAverage": 3.0972, "twoHundredDayAverage": 2.72205, "currency": "USD", "enterpriseValue": 150101904, "floatShares": 25998811, "sharesOutstanding": 34538200, "sharesShort": 1866176, "sharesShortPriorMonth": 1625415, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.054, "heldPercentInsiders": 0.16633, "heldPercentInstitutions": 0.14156, "shortRatio": 7.02, "shortPercentOfFloat": 0.0641, "impliedSharesOutstanding": 34538200, "bookValue": 0.97, "priceToBook": 5.5051546, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -27660000, "trailingEps": -0.94, "forwardEps": -0.94, "enterpriseToRevenue": 18762.738, "enterpriseToEbitda": -5.234, "52WeekChange": -0.26612902, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.34, "targetHighPrice": 30.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.4, "targetMedianPrice": 19.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 34057000, "totalCashPerShare": 0.999, "ebitda": -28676000, "totalDebt": 2039000, "quickRatio": 6.131, "currentRatio": 6.475, "totalRevenue": 8000, "debtToEquity": 6.162, "returnOnAssets": -0.48675, "returnOnEquity": -0.96849996, "grossProfits": 8000, "freeCashflow": -13646875, "operatingCashflow": -23836000, "grossMargins": 1.0, "operatingMargins": -3618.625, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]